Table 2.
Summary of outcomes for ablation of neuroendocrine liver metastases.
| Author, publication year | Number of ablated patients | Median followup, months | Survival data | Comments |
|---|---|---|---|---|
| Karabulut et al., 2011 [16] | 69 (RFA) |
22 | Median PFS: 10.5 months Median OS: 73 months |
No significant overall survival difference between RFA and resection |
|
| ||||
| Akyildiz et al., 2010 [23] | 89 (RFA; 78 with NETs of GI origin, 11 medullary thyroid cancer) |
30 | Median DFS: 15.6 months Median OS: 72 months |
Liver tumor volume (>76 cc versus <30 cc, P = .04), symptoms (present versus absent, P = .04), extrahepatic disease (present versus absent, P = .02) |
|
| ||||
| Martin et al., 2010 [24] | 11 (MWA; 7 with concomitant hepatectomy; 6 with concomitant extrahepatic resection) |
36 | Median DFS: 8 months Median OS: 18 months |
Zero recurrences at ablation site |
|
| ||||
| Mazzaglia et al., 2007 [25] | 63 (RFA; 24 with extrahepatic disease at time of 1st ablation) |
34 | Median OS: 47 months after 1st RFA 5-year survival: 48% |
Male gender (3x mortality risk of female) (P = .04), largest tumor > 3 cm (P = .03) |
|
| ||||
| Gillams and Lees, 2005 [26] | 25 (RFA) |
21 (in 19 patients) | Median OS: 29 months | Shorter survival (23 months) in carcinoid patients |
|
| ||||
| Seifert et al., 1998 [27] | 13 (cryoablation) |
13.5 | 12 patients alive at the end of followup (up to 103 months) | All 7 symptomatic patients had subjective improvement |
|
| ||||
| Shapiro et al., 1998 [28] | 5 (cryoablation) |
30 | 1-year survival: 60% 2-year survival: 40% |
All 5 patients had relief of carcinoid syndrome |